Laboratory informatics based evaluation of methylene tetrahydrofolate reductase C677T genetic test overutilization

Background: Laboratory data can provide a wide range of information to estimate adherence to guidelines and proper utilization of genetic testing. The methylene tetrahydrofolate reductase (MTHFR) C677T variant has been demonstrated to have negligible utility in patient management. However, the testing of this variant remains pervasive. The purpose of this study was to develop methods to analyze concordance of clinician ordering practices with national guidelines. Methods: We used laboratory data to extract specific data elements including patient demographics, timestamps, physician ordering logs and temporal relationship to chemistry requests to examine 245 consecutive MTHFR tests ordered in 2011 at an academic tertiary center. A comprehensive chart review was used to identify indications for testing. These results were correlated with a retrospective analysis of 4,226 tests drawn at a range of hospitals requesting testing from a national reference laboratory over a 2-year period. MTHFR ordering practices drawn from 17 institutions were examined longitudinally from 2002 to 2011. Results: Indications for testing included cerebrovascular events (40.0%) and venous thrombosis (39.1%). Family history prompted testing in eight cases. Based on acceptable hypercoagulability guidelines recommending MTHFR C677T testing only in the presence of elevated serum homocysteine, 10.6% (22/207) of adult patients met an indicated threshold at an academic tertiary center. Among 77 institutions, 14.5% (613/4226) of MTHFR testing met recommendations. Conclusion: We demonstrate an effective method to examine discreet elements of a molecular diagnostics laboratory information system at a tertiary care institution and to correlate these findings at a national level. Retrospective examination of clinicians′ request of MTHFR C677T genetic testing strongly suggests that clinicians have failed to adjust their ordering practices in light of evolving scientific and professional organization recommendations.

[1]  T. Ramón Y Cajal,et al.  What factors may influence psychological well being at three months and one year post BRCA genetic result disclosure? , 2012, Breast.

[2]  Elaine Gray,et al.  Clinical guidelines for testing for heritable thrombophilia , 2010, British journal of haematology.

[3]  Robert Cook-Deegan,et al.  Disclosure of APOE genotype for risk of Alzheimer's disease. , 2009, The New England journal of medicine.

[4]  Brian H Shirts,et al.  Changing interpretations, stable genes: responsibilities of patients, professionals, and policy makers in the clinical interpretation of complex genetic information , 2008, Genetics in Medicine.

[5]  J. Hirsh,et al.  Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). , 2008, Chest.

[6]  P. Romundstad,et al.  Prospective study of homocysteine and MTHFR 677TT genotype and risk for venous thrombosis in a general population – results from the HUNT 2 study , 2008, British journal of haematology.

[7]  J. Caprini,et al.  Hyperhomocysteinemia and thrombosis: an overview. , 2007, Archives of pathology & laboratory medicine.

[8]  F. Rosendaal,et al.  No association between the common MTHFR 677C->T polymorphism and venous thrombosis: results from the MEGA study. , 2007, Archives of internal medicine.

[9]  B. Dallapiccola,et al.  Genetic testing in Italy, year 2004 , 2006, European Journal of Human Genetics.

[10]  R. Clarke,et al.  Homocysteine, MTHFR and risk of venous thrombosis: a meta‐analysis of published epidemiological studies , 2005, Journal of thrombosis and haemostasis : JTH.

[11]  A. Sturm,et al.  Cardiology patient pages. Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. , 2005, Circulation.

[12]  M. Hessner,et al.  Detection of genomic polymorphisms associated with venous thrombosis using the invader biplex assay. , 2004, The Journal of molecular diagnostics : JMD.

[13]  S. Vollset,et al.  Geographical and ethnic variation of the 677C>T allele of 5,10 methylenetetrahydrofolate reductase (MTHFR): findings from over 7000 newborns from 16 areas world wide , 2003, Journal of medical genetics.

[14]  A. Folsom,et al.  Serum homocysteine, thermolabile variant of methylene tetrahydrofolate reductase (MTHFR), and venous thromboembolism: Longitudinal investigation of thromboembolism etiology (LITE) , 2003, American journal of hematology.

[15]  W. Grody,et al.  American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing , 2001, Genetics in Medicine.

[16]  Quanhe Yang,et al.  5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. , 2000, American journal of epidemiology.

[17]  M. Margaglione,et al.  The Methylenetetrahydrofolate Reductase TT677 Genotype Is Associated with Venous Thrombosis Independently of the Coexistence of the FV Leiden and the Prothrombin , 1998, Thrombosis and Haemostasis.

[18]  F. Costa,et al.  The Mutation Ala677→Val in the Methylene Tetrahydrofolate Reductase Gene: A Risk Factor for Arterial Disease and Venous Thrombosis , 1997, Thrombosis and Haemostasis.

[19]  J. Yarnell,et al.  The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. , 1996, QJM : monthly journal of the Association of Physicians.

[20]  R. Matthews,et al.  A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase , 1995, Nature Genetics.